If you have been reading about AOD-9604 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-04-07. Where a claim depends on a specific study, the study is described rather than over-claimed.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; may appear as cake |
| Solubility class | Water-soluble | Often reconstituted in aqueous buffer |
| Typical storage temperature | −20 °C or below | Protect from light and moisture |
| Typical analytical method | RP-HPLC and mass spectrometry | Used for purity and identity |
| Common synonyms | AOD-9604; AOD9604; hGH fragment 176-191 | Research name and fragment description |
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Juvenile idiopathic arthritis (JIA), also known as juvenile arthritis and formerly known as juvenile rheumatoid arthritis (JRA), is the most common chronic rheumatic disease of childhood, affecting approximately 3.8 to 400 out of 100,000 children. Juvenile refers to disease onset before 16 years of age, while idiopathic refers to a condition with no defined cause, and arthritis is inflammation within the joint. JIA is an autoimmune, noninfective, inflammatory joint disease, the cause of which remains poorly understood. It is characterised by chronic joint inflammation. JIA is a subset of childhood arthritis, but unlike other, more transient forms of childhood arthritis, JIA is a lifelong condition with relapse of disease after treatment discontinuation being common. JIA has clinical and pathologic correlates to adult inflammatory and auto-immune arthritis, with the diseases believed to exist on a continuum from childhood to adulthood. There are six biologically and clinically distinct forms of JIA: oligoarticular JIA, rheumatoid factor negative polyarticular JIA, rheumatoid factor positive polyarticular JIA, enthesitis-related arthritis, psoriatic JIA and systemic JIA. A definitive diagnostic test for JIA is lacking: diagnosis is made clinically by a combination of laboratory and clinical factors. Cancer and other auto-immune or inflammatory conditions are usually considered. The prognosis for children with JIA has improved dramatically over recent decades, particularly with the introduction of biological therapies and a shift towards more aggressive treatment strategies.
==== Hydrogen adsorption ==== Adsorption is the process of trapping atoms or molecules that are incident on a surface; therefore the adsorption capacity of a material increases with its surface area. In three dimensions, the maximum surface area will be obtained by a structure which is porous, such that atoms and molecules can access internal surfaces. This simple qualitative argument suggests that the porous metal-organic frameworks (MOFs) should be excellent candidates for hydrogen storage devices. Adsorption can be broadly classified as being one of two types: physisorption or chemisorption. Physisorption is characterized by weak van der Waals interactions, and bond enthalpies typically less than 20 kJ/mol. Chemisorption, alternatively, is defined by stronger covalent and ionic bonds, with bond enthalpies between 250 and 500 kJ/mol. In both cases, the adsorbate atoms or molecules (i.e. the particles which adhere to the surface) are attracted to the adsorbent (solid) surface because of the surface energy that results from unoccupied bonding locations at the surface. The degree of orbital overlap then determines if the interactions will be physisorptive or chemisorptive. Adsorption of molecular hydrogen in MOFs is physisorptive. Since molecular hydrogen only has two electrons, dispersion forces are weak, typically 4–7 kJ/mol, and are only sufficient for adsorption at temperatures below 298 K.
=== Optical isomerism === Glutamic acid is chiral; two mirror-image enantiomers exist: d(−), and l(+). The l form is more widely occurring in nature, but the d form occurs in some special contexts, such as the bacterial capsule and cell walls of bacteria (which produce it from the l form with the enzyme glutamate racemase) and can be found in small amounts in the liver and other organs of mammals, either directly from dietary sources or from production by the gut microbiota.
Amid the dismantling of apartheid in the early 1990s, various political parties competed over Biko's legacy, with several saying they were the party that Biko would support if he were still alive. AZAPO in particular claimed exclusive ownership over Black Consciousness. In 1994, the ANC issued a campaign poster suggesting that Biko had been a member of their party, which was untrue. Following the end of apartheid when the ANC formed the government, they were accused of appropriating his legacy. In 2002, AZAPO issued a statement declaring that "Biko was not a neutral, apolitical and mythical icon" and that the ANC was "scandalously" using Biko's image to legitimise their "weak" government. Members of the ANC have also criticised AZAPO's attitude to Biko; in 1997, Mandela said that "Biko belongs to us all, not just AZAPO." On the anniversary of Biko's death in 2015, delegations from both the ANC and the Economic Freedom Fighters independently visited his grave. In March 2017, the South African President Jacob Zuma laid a wreath at Biko's grave to mark Human Rights Day.
==== Distribution ==== The drug is distributed widely throughout the body, including in saliva, bile, cerebrospinal fluid, synovial fluids, and pleural effusions. In accordance with its presence in cerebrospinal fluid, methenamine is known to cross the blood–brain barrier and enter the central nervous system. The volume of distribution and plasma protein binding of methenamine are unknown.
Sources: en.wikipedia.org
== Young adults == By far, the most common cause of severe hypoglycemia in this age range is insulin injected for type 1 diabetes. Circumstances should provide clues fairly quickly for the new diseases causing severe hypoglycemia. All of the congenital metabolic defects, congenital forms of hyperinsulinism, and congenital hypopituitarism are likely to have already been diagnosed or are unlikely to start causing new hypoglycemia at this age. Body mass is large enough to make starvation hypoglycemia and idiopathic ketotic hypoglycemia quite uncommon. Recurrent mild hypoglycemia may fit a reactive hypoglycemia pattern, but this is also the peak age for idiopathic postprandial syndrome, and recurrent "spells" in this age group can be traced to orthostatic hypotension or hyperventilation as often as demonstrable hypoglycemia.
=== Discovery of PtdIns(5)P === In 1997, the Cantley lab discovered that the enzymes that had been referred to as type II PIP-kinases, instead of using PtdIns(4)P as a substrate, in fact required PtdIns(5)P as a substrate to produce PtdIns(4,5)P2. Further research demonstrated that PtdIns(5)P is naturally occurring in all eukaryotes. Of the seven naturally occurring phosphoinositides, the existence of four of them (PtdIns(5)P, PtdIns(3)P, PtdIns(3,4)P2, and PtdIns(3,4,5)P3) was discovered by Cantley and colleagues.
Tianeptine, sold under the brand names Stablon, Tatinol, and Coaxil among others, is an atypical tricyclic antidepressant which is used mainly in the treatment of major depressive disorder, although it may also be used to treat anxiety, asthma, and irritable bowel syndrome. Tianeptine has antidepressant and anxiolytic effects with a relative lack of sedative, anticholinergic, and cardiovascular side effects. It has been found to act as an atypical agonist of the μ-opioid receptor with clinically negligible effects on the δ- and κ-opioid receptors. This may explain part of its antidepressant and anxiolytic effects; however, it is thought that tianeptine also modulates glutamate receptors, and this may also explain tianeptine's antidepressant/anxiolytic effects. Tianeptine was discovered and patented by the French Society of Medical Research in the 1960s. It was introduced for medical use in France in 1983. Currently, tianeptine is approved in France and manufactured and marketed by Laboratories Servier SA; it is also marketed in a number of other European countries under the trade name Coaxil as well as in Asia (including Singapore) and Latin America as Stablon and Tatinol but it is not available in Australia, Canada, New Zealand, Italy or the United Kingdom. In the United States, it is an unregulated drug sold under several names and some of these products have been found to be adulterated with other recreational drugs. It is commonly known by the nickname "gas station heroin".
When the fruit is ripe, it is almost always hand-picked, using either "selective picking", where only the ripe fruit is removed, or "strip-picking", where all of the fruit is removed from a limb all at once. Selective picking yields higher-quality coffee because the cherries are picked at their ripest. Indiscriminate strip-picking harvests unripe, ripe, and over-ripe fruit, requiring sorting after picking. Two methods are primarily used to process coffee berries. The first, "wet" or "washed" process, has historically usually been carried out in Central America and areas of Africa. The flesh of the cherries is separated from the seeds and then the seeds are fermented by soaking in water for about two days. This softens the mucilage, a sticky pulp residue attached to the seeds; it is then washed off with water. The "dry processing" method, cheaper and simpler, was historically used for lower-quality beans in Brazil and much of Africa, but now brings a premium when done well. Twigs and other foreign objects are separated from the berries, and the fruit is then spread out in the sun on concrete, bricks or raised beds for two to three weeks, turned regularly for even drying. In Asia, a third type of processing is occasionally used: the Asian palm civet eats coffee berries and excretes the beans. The civet chooses to harvest the ripest cherries; its digestive system then processes the beans by breaking down the mucilage and pulp surrounding the seed. Once the seeds are excreted by the civet, they can be harvested, processed and sold as a niche product.
Sources: en.wikipedia.org
== Other candies under the brand == Grapeheads (Discontinued) Cherryheads (Discontinued) Appleheads (Discontinued) Orangeheads (Discontinued) Chewy Lemonheads and Friends (including Lemonheads, Grapeheads, Cherryheads, Appleheads, and Orangeheads) (discontinued) Chewy Lemonheads Tropical (discontinued) Chewy Lemonheads Fruit Mix (discontinued) Chewy Lemonheads Flavor Fusers (discontinued) Chewy Lemonheads Pink Lemonade (discontinued) Lemonhead Ropes JuicyHeads (discontinued) BlueRaspberryheads (Discontinued) Raspberryheads (Discontinued) BlackRaspberryheads (Discontinued) LoveHeads (Discontinued) Lemonhead Freeze Dried
Mean Absolute Relative Difference (MARD) is a standard metric used to evaluate the accuracy of continuous glucose monitoring systems, which gives the average amount a CGM sensor reading varies from the actual blood glucose. It is calculated by taking the average of the absolute relative differences between the glucose readings reported by the CGM system and corresponding reference measurements, typically obtained through laboratory analysis or blood glucose meters. A lower MARD value indicates greater accuracy, and it is commonly used in clinical research and regulatory evaluations to compare the performance of different CGM devices. It is also of note that MARD percentages can vary by person, even while using the same device. The accuracy of Dexcom CGM systems has steadily improved over time, as reflected in declining MARD values across successive generations. The original Dexcom STS, released in 2006, had a MARD of approximately 20.3%, while the Dexcom Seven, introduced in 2007, reduced this to around 17%. The Seven Plus had a slightly lower MARD of 16%. The G4 Platinum, launched in 2012, further improved accuracy with a MARD of 13.9%, followed by the G5 Mobile in 2015, which achieved 9%—the first Dexcom system to reach single-digit accuracy. in some users, however it also was found to be as high as 15%. The Dexcom G6, released in 2018, was similarly marketed with a MARD of 9%, although some studies found values exceeding 12% in certain individuals.
== Treatment == Copper deficiency is a very rare disease and is often misdiagnosed several times by physicians before concluding the deficiency of copper through differential diagnosis (copper serum test and bone marrow biopsy are usually conclusive in diagnosing copper deficiency). On average, patients are diagnosed with copper deficiency around 1.1 years after their first symptoms are reported to a physician. Copper deficiency can be treated with either oral copper supplementation or intravenous copper. If zinc intoxication is present, discontinuation of zinc may be sufficient to restore copper levels to normal, but this usually is a very slow process. People with zinc intoxication will usually have to take copper supplements in addition to ceasing zinc consumption. Hematological manifestations are often quickly restored to normal. The progression of the neurological symptoms will be stopped and sometimes improved with appropriate treatment, but residual neurological disability is common.
Sources: en.wikipedia.org
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.
Reversed-phase HPLC and mass spectrometry are standard checks. They confirm peptide purity and molecular mass, but they do not by themselves demonstrate biological activity.
Synthesis, purification, and handling conditions can differ, leading to variations in purity and salt content. Certificates of analysis help, but independent testing is often needed for verification.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.